Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Talk outline
- Brief history of MDSC
- Overview on MDSC
- Immune tolerance and suppression
- MDSC in tumor vs. peripheral lymphoid organs
- Accumulation of MDSC in tumor models
- Immature myeloid cells in tumor-bearing host
- MDSC in lymph nodes
- Subsets of myeloid-derived suppressor cells
- Differentiating two subsets of MDSC
- PMN-MDSC (main subset of suppressor cells)
- PMN-MDSC can derive from M-MDSC
- PMN-MDSC in cancer
- T cell suppressive activity: Lin-HLA-DR-CD33+
- T cell suppressive activity: CD14-CD11b+CD33+
- Mechanisms regulating MDSC expansion
- Potential models of MDSC accumulation
- Signaling pathways involved in MDSC expansion
- Signaling pathways involved in MDSC activation
- Hyperactivation of JAK2 and STAT-3 in MDSC
- The STAT-3 axis involved in MDSC regulation
- Mechanisms of MDSC activity
- Mechanisms of immune suppression by MDSC
- Immune suppression and MDSC sub-populations
- MDSC-induced CD8+ T cell tolerance
- Main mechanism of T cell tolerance
- MDSC cause nitration of TCR on CD8+ T cells
- MDSC interaction with CD8+ T cells
- How MDSC cause T cell tolerance
- Expression of MHC class I and class II on MDSC
- Antigen-specific suppression & MHC class II
- MDSC from MC38 mice cause tolerance
- MDSC-inducible T cell tolerance & MHC class II
- Antigen-specific CD4+ T cells convert MDSC
- Direct cell-cell contact is needed for conversion
- Absence of the antigen & conversion failure
- Cross-linking of MHC class II & MDSC conversion
- Expression due to cross-linking of MHC class II
- Inhibition of COX2 blocked effect of cross-linking
- Inhibition of COX2 in vivo
- Interaction of MDSC with CD4+ T cells
- MDSC effect in peripheral lymphoid organs
- Interaction of MDSC with CD4+ T cell subsets
- MDSC effect on tumor progression
- MDSC migration to the tumor site
- Tumor metastases and subsets of MDSC
- Therapeutic targeting of MDSC in cancer
- Overview of therapeutic agents
- Summary
- Acknowledgments
Topics Covered
- Myeloid derived suppressor cells (MDSC) and their potent immune suppressive activity
- MDSC in cancer
- MDSC in chronic infections
- MDSC during stress
- MDSC in surgical trauma
- The two main populations of MDSC: monocytic MDSC (M-MDSC) and polymorphonuclear MDSC (PMN-MDSC)
- Biological differences between MDSC and their normal counterparts
- Multiple mechanisms of expansion regulation and immune suppressive function of MDSC
- MDSC role in antigen-specific T cell tolerance in tumor-bearing mice
- Therapeutic regulation of MDSC in mice and humans
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Gabrilovich, D. (2014, December 2). Immunosuppressive mechanisms in myeloid cells [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/ZLHZ6081.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Gabrilovich is an employee and stakeholder of AstraZeneca, however no products of AstraZeneca or any other companies are discussed.
Other Talks in the Series: Immunotherapy of Cancer
Transcript
Please wait while the transcript is being prepared...
0:00
Hi.
My name is Dimitry Gabrilovich.
I am head of the Tumor Immunology
Program in Wistar Institute
and Professor to University of
Pennsylvania in Philadelphia.
I am going to talk to you about
myeloid-derived suppressor
cells in tumors.
0:16
What we'll discuss, the
following topics today.
First, we will discuss a definition
of myeloid-derived suppressor
cells, then the main
characteristics, followed
by molecular mechanisms regulating
myeloid-derived suppressor cell
expansion, and mechanism of
myeloid-derived suppressor cell
activity, primarily, the
inhibitory effect on T cells.
We will talk about
therapeutic targeting
of myeloid-derived
suppressor cells in cancer
at the end of the presentation.
0:45
Myeloid cells with
immunosuppressive features
have been known since the late '70s.
Investigators describe appearances
of these cells in response
to stimulation with
different growth factors.
The first evidence that these
cells could be involved in tumor
development or associated
with the tumor development
have been recorded in mid-90s.
And they become the focus of more
intensive studies in early 2000.
The term of myeloid-derived
suppressor cells
has been introduced in 2007.
And these days, these cells
become the focus of intensive studies
by many groups in different
conditions, primarily in cancer.
1:29
As we know, myeloid cells
differentiate in bone marrow
through the sequential
steps involved
in several different progenitors
from hematopoietic stem cells
through the common
myeloid progenitors,
and they end up in
three major classes
of terminally differentiated
mature myeloid cells, neutrophils,
or granulocytes, some
macrophages, or dendritic cells.
In cancer, tumor and
tumor-associated stroma
produce multiple different
cytokines which dramatically
affect differentiation
of myeloid cells.
The end result of this
process is accumulation,
in some cases, dramatic
accumulation, of cells which are
characterized myeloid lineages,
but also, the relatively immature
phenotype and a very
important ability
to suppress immune
function; therefore,
the cell, so-called
myeloid-derived suppressor cells.
And I will refer to them as MDSC
for simplicity in the next slides.